An interventional study of COX-2 inhibitor and Placebo Oral Tablet in Female Genital Disease, sponsored by Seoul National University Hospital. Status unknown at 1 site in Korea, Republic of. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-01-05.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Genital Diseases, Female with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Genital Diseases, Female · Korea, Republic of.
Among the 20 studies in Genital Diseases, Female with a site in Korea, Republic of, this one is the 14th largest by planned enrollment, is the only one that started in 2017, is one of 14 with no phase, and was the 12th registered.
161 studies on the registry are indexed under Genital Diseases, Female; 31 are open to participants now.
Browse Genital Diseases, Female studies →None of the 20 studies in Genital Diseases, Female with a site in Korea, Republic of is open now. The open studies under Genital Diseases, Female, anywhere →
Of the 21 Genital Diseases, Female studies recruiting now, 10 (48%) set no upper age limit and 11 (52%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 78 across 119 interventional studies indexed under Genital Diseases, Female.
Median enrollment 79 across the 20 interventional studies. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
Seoul National University Hospital is the lead sponsor of 1,900 studies on the registry; 274 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Seoul National University Hospital has 3 studies filed under Genital Diseases, Female — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Genital Diseases, Female with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare postoperative pain following COX-2 and prostanoids expression in women who underwent laparoscopic surgery for female genital disease in order to evaluate the effect of COX-2 on local inflammation, COX-2 and prostanoids expression followed by exposure time to carbon dioxide(CO2) gas, and degree of postoperative pain.
In women who underwent laparoscopic surgery for female genital disease, the effect of COX-2 on local inflammation was assessed by randomization, using the COX-2 inhibitor celecoxib and placebo, comparative evaluation of expression of COX-2 and prostanoids by pre/postoperative peritoneal biopsy and postoperative pain depending on gas exposure time
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Celebrex; COX-2 inhibitor
Drug: COX-2 inhibitor · Procedure: Preoperative peritoneal biopsy · Procedure: Single-port laparoscopic surgery · Procedure: Postoperative peritoneal biopsy
Ramnos; Lactobacillus casei variety rhamnosus
Drug: Placebo Oral Tablet · Procedure: Preoperative peritoneal biopsy · Procedure: Single-port laparoscopic surgery · Procedure: Postoperative peritoneal biopsy
Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery
Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery
Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
Single-port laparoscopic surgery with CO2 gas
Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
Change of biomarkers expression according to exposure to CO2 gas
Peritoneal biopsy and real-time polymerase chain reaction(RT-PCR), Immunohistochemistry of Biomarkers (COX-2, PGE2, PGF2, PGI2, TXA2)
Time frame: Peritoneal biopsy will be done twice (intraoperative, at right after trocar insertion and right before trocar removal, an average of 2-3hours)
Visual analogue scale(VAS) score
Degree of postoperative pain (No pain : 0 / Moderate pain : 5 / Unbearable pain : 10)
Time frame: every six hours for 48 hours
Numbers of rescue analgesia
Frequency of additional pain killer (Tramadol 50mg, Ketorolac 2mg/kg)
Time frame: From postoperation state to discharge (up to 2 days)
Postoperative complication
nausea, vomiting, etc.
Time frame: From postoperation state to discharge (up to 2 days)
Duration of hospitalization
duration of hospitalization
Time frame: From postoperation state to discharge (up to 2 days)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2017 (actual). Primary completion is estimated for Oct 2019, 24 months after the start.
Of 55 non-industry interventional studies with no phase under Genital Diseases, Female, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's planned 24 months is above that.
Counting every sponsor, half of 65 studies reached it within 14 months; a quarter within 8 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: COX-2 inhibitors
Seoul National University Hospital →